Applied Genetic Technologies plans public offering of 2 million shares

BMO Capital, Stifel, Wedbush are to be the joint bookrunning managers

By Devika Patel

Knoxville, Tenn., July 11 – Applied Genetic Technologies Corp. will price a public sale of 2 million common shares with a 30-day greenshoe option of 300,000 additional shares, according to a Form S-1 filed Friday with the Securities and Exchange Commission.

BMO Capital Markets, Stifel and Wedbush PacGrow Life Sciences are the joint bookrunning managers. Cantor Fitzgerald & Co. and Roth Capital Partners are the co-managers.

Proceeds will be used for preclinical investigation and Phase ½ trials, to expand manufacturing capabilities, to in-license, acquire or invest in complementary gene therapy technologies, products or assets and for working capital and other general corporate purposes.

The clinical-stage biotechnology company is based in Alachua, Fla.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.